HIGHLIGHTS
- who: Sarah Stapleton u200d u200d et al. from the UK University of Southampton have published the research: What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed- methods exploratory study conducted in an early clinical trials unit, in the Journal: BMJ Open 2022;12:e050590. of /2022/
- what: At this stage of drug development, the main aims are to find the optimal dose, investigate the pharmacology and to define the toxicity profiles . The paper reports that 46% (n=115) have all grade . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.